Regulators have handed back Adventrx's NDA for a new formulation of Taxotere, saying the developer needs to perform a study that proves the new drug is biologically equivalent to the original. The news caused the biotech's shares to slip six percent. The biotech is likely to perform the study at the same time it tests the chemical stability of ANX-514 over a two-year period. Report